Skip to main content

Advertisement

SpringerLink
Log in

Prediction of Decompensation in Patients with Compensated Cirrhosis: Does Etiology Matter?

  • Portal Hypertension (J Gonzalez-Abraldes and E Tsochatzis, Section Editors)
  • Published:
Current Hepatology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

Transition from compensated to decompensated cirrhosis, defined by overt clinical signs, represents a turning point in the clinical course of the disease. In fact, while compensated cirrhosis is a silent disease characterized by long survival, decompensated cirrhosis is associated with symptoms markedly reducing the quality of life and with a median survival of 2–4 years. Therefore, identifying predictors of decompensation and investigating potential interventions for its prevention is a major objective. Mechanisms and incidence of decompensation, together with its predictors, are summarized here, with regard to the etiology of the disease.

Recent Findings

In a total of 92 studies including 105 cohorts and 152,320 patients, the mean ± SD 5-year decompensation rate was 24.5 ± 13.6%. The 5-year decompensation rate was significantly different across different etiologies, ranging from 12.8% for biliary etiologies to 33.6% in alcoholic liver disease (p < 0.0001). The most frequently reported significant predictors of decompensation were liver function, portal hypertension, and inflammation/fibrosis indicators. Etiologic treatment was associated with significant risk reduction.

Summary

While the risk of decompensation significantly varies across different etiologies of cirrhosis, etiology per se has not been properly studied as a decompensation predictor. Although decompensation appears to be related more to inflammation/fibrosis and portal hypertension, the causing factors may determine different activation intensity of the decompensating mechanisms.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Ginés P, Quintero E, Arroyo V, Terés J, Bruguera M, Rimola A, et al. Compensated cirrhosis: natural history and prognosis. Hepatology. 1987;7(1):122–8.

    Article  PubMed  Google Scholar 

  2. Saunders JB, Walters JRF, Davies P, Paton A. A 20-year prospective study of cirrhosis. Br Med J. 1981;282(6260):263–6.

    Article  CAS  Google Scholar 

  3. D’Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006;44(1):217–31.

    Article  PubMed  Google Scholar 

  4. Garcia-Tsao G, Friedman S, Iredale J, Pinzani M. Now there are many stages where before there was one: in search of pathophysiological classification of cirrhosis. Hepatology. 2010;51(4):1445–9. https://doi.org/10.1002/hep.23478.

    Article  PubMed  Google Scholar 

  5. Bedossa P, Garcia-Tsao G, Jain D. Cirrhosis regression and subclassification. Surg Pathol Clin. 2013;6(2):295–309. https://doi.org/10.1016/j.path.2013.03.006.

    Article  PubMed  Google Scholar 

  6. D’Ambrosio R, Aghemo A, Rumi MG, Ronchi G, Donato MF, Paradis V. A morphometric and immunoistochemical study to assess the benefit of sustained virological response in hepatitis c virus patients with cirrhosis. Hepatology. 2012;56(2):532–43. https://doi.org/10.1002/hep.25606.

    Article  PubMed  Google Scholar 

  7. Vorobioff J, Groszmann R, Picabea E, Gamen M, Villavicenzcio R, Bordato J, et al. Prognostic value of hepatic venous pressure gradient measurements in alcoholic cirrhosis: a 10-year prospective study. Gastroenterology. 1996;111(3):701–9.

    Article  CAS  PubMed  Google Scholar 

  8. •• Berzigotti A, Albillos A, Villanueva C, Genescá J, Ardevol A, Augustín S, et al. Effects of an intensive lifestyle intervention program on portal hypertension patients with cirrhosis and obesity: the SportDiet study. Hepatology. 2017;65(4):1293–305. https://doi.org/10.1002/hep.28992 Provides evidence that etiologic cure in obese patients with cirrhosis improves outcome targeting pathophysiologic mechanisms.

    Article  PubMed  Google Scholar 

  9. •• Mandorfer M, Kozbial K, Schwabl P, Freissmuth C, Schwarzer R, Stern R, et al. Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension. J Hepatol. 2016;65(4):692–9. https://doi.org/10.1016/j.jhep.2016.05.027 Provides evidence that etiologic cure in HCV cirrhosis improves outcome targeting pathophysiologic mechanisms.

    Article  PubMed  Google Scholar 

  10. Iwakiri Y, Groszmann RJ. The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule. Hepatology. 2006;43(Suppl. 1):S121–31.

    Article  CAS  PubMed  Google Scholar 

  11. Abraldes JG, Iwakiri Y, Loureiro-Silva M, Haq O, Sessa WC, Groszmann RJ. Mild increases in portal pressure up-regulate VEGF and eNOS in the intestinal microcirculation leading to hyperdynamic state. Am J Physiol Gastrointest Liver Physiol. 2006;290:G980–7.

    Article  CAS  PubMed  Google Scholar 

  12. Møller S, Hobolth L, Winkler C, Bendtsen F, Christensen E. Determinants of the hyperdynamic circulation and central hypovolaemia in cirrhosis. Gut. 2011;60(9):1254–9. https://doi.org/10.1136/gut.2010.235473.

    Article  PubMed  Google Scholar 

  13. Nagula S, Jain D, Groszmann RJ, Garcia-Tsao G. Histological–hemodynamic correlation in cirrhosis—a histological classification of the severity of cirrhosis. J Hepatol. 2006;44(1):111–7. https://doi.org/10.1016/j.jhep.2005.07.036.

    Article  PubMed  Google Scholar 

  14. Sethasine S, Jain D, Groszmann R, Garcia-Tsao R. Quantitative histological-hemodynamic correlations in cirrhosis. Hepatology. 2012;55(4):1146–53. https://doi.org/10.1002/hep.24805.

    Article  PubMed  Google Scholar 

  15. Calvaruso V, Burroughs AK, Standish R, Manousou P, Grillo F, Leandro G, et al. Computer-assisted image analysis of liver collagen: relationship to Ishak scoring and hepatic venous pressure gradient. Hepatology. 2009;49(4):1236–44. https://doi.org/10.1002/hep.22745.

    Article  PubMed  Google Scholar 

  16. •• Villanueva C, Albillos A, Jenescà J, Abraldes J, Calleca JL, Aracil C, et al. Development of hyperdynamic circulation and response to β-blockers in compensated cirrhosis with portal hypertension. Hepatology. 2016;63(1):197–206. https://doi.org/10.1002/hep.28264 First study showing the importance of clinically significant portal hypertension in determining the response to non selective beta-blochers.

    Article  CAS  PubMed  Google Scholar 

  17. De Franchis R. Updating consensus in portal hypertension: report of the Baveno III consensus workshop on definitions, methodology and therapeutic strategies in portal hypertension. J Hepatol. 2000;33(5):846–52.

    Article  PubMed  Google Scholar 

  18. Groszmann RJ, Garcia-Tsao G, Bosch J, Grace ND, Burroughs AK, Planas R, et al. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med. 2005;353(21):2254–61. https://doi.org/10.1056/NEJMoa044456.

    Article  CAS  PubMed  Google Scholar 

  19. Merli M, Nicolini G, Angeloni S, Rinaldi V, De Santis A, Merkel C, et al. Incidence and natural history of small esophageal varices in cirrhotic patients. J Hepatol. 2003;38(3):266–72.

    Article  PubMed  Google Scholar 

  20. D’Amico G, Pasta L, Madonia S, Tarantino IG, Mancuso A, Malizia G, et al. The incidence of esophageal varices in cirrhosis. Gastroenterology. 2001;120(Suppl. 1):A2.

    Article  Google Scholar 

  21. D’Amico G, Pasta L, Morabito A, D’Amico M, Caltagirone M, Malizia G, et al. Competing risks and prognostic stages in cirrhosis: a 25-year inception cohort study of 494 patients. Aliment Pharmacol Ther. 2014;39(10):1180–93. https://doi.org/10.1111/apt.12721.

    Article  PubMed  Google Scholar 

  22. Gomez Vilar E, Rodriguez YS, Bertot LC, Gonzalez AT, Perez YM, Soler EA, et al. The natural history of compensated HCV-related cirrhosis: a prospective long-term study. J Hepatol. 2013;58(3):434–44. https://doi.org/10.1016/j.jhep.2012.10.023.

    Article  Google Scholar 

  23. Jepsen P, Ott P, Andersen PK, Sørensen HT, Vilstrup H. Clinical course of alcoholic liver cirrhosis: a Danish population-based cohort study. Hepatology. 2010;51(5):1675–82. https://doi.org/10.1002/hep.23500.

    Article  PubMed  Google Scholar 

  24. Zoli M, Merkel C, Magalotti D, Gueli C, Grimaldi M, Gatta A, et al. Natural history of cirrhotic patients with small esophageal varices: a prospective study. Am J Gastro. 2000;95(2):503–8. https://doi.org/10.1111/j.1572-0241.2000.01775.x.

    Article  CAS  Google Scholar 

  25. North Italian Endoscopic Club for the Study and Treatment of Esophageal Varices. Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices. A prospective study. N Engl J Med. 1988;319(15):983–9. https://doi.org/10.1056/NEJM198810133191505.

    Article  Google Scholar 

  26. Reverter E, Tandon P, Augustin S, Turon F, Casu S, Bastiampillai R, et al. A MELD-based model to determine risk of mortality among patients with acute variceal bleeding. Gastroenterology. 2014;146(2):412–19.e3. https://doi.org/10.1053/j.gastro.2013.10.018.

    Article  PubMed  Google Scholar 

  27. D’Amico G, De Franchis R, Cooperative Study Group. Upper digestive bleeding in cirrhosis. Post-therapeutic outcome and prognostic indicators. Hepatology. 2003;38(3):599–612. https://doi.org/10.1053/jhep.2003.50385.

    Article  PubMed  Google Scholar 

  28. Bernard B, Lebrec D, Mathurin P, Opolon P, Poynard T. Beta-adrenergic antagonists in the prevention of gastrointestinal rebleeding in patients with cirrhosis: a meta-analysis. Hepatology. 1997;25(1):63–70. https://doi.org/10.1053/jhep.1997.v25.pm0008985266.

    Article  CAS  PubMed  Google Scholar 

  29. D’Amico G, Pagliaro L, Bosch J. Pharmacological treatment of portal hypertension: an evidence-based approach. Semin Liver Dis. 1999;19(4):475–505. https://doi.org/10.1055/s-2007-1007133.

    Article  PubMed  Google Scholar 

  30. Gonzalez R, Zamora J, Gomez-Camarero J, Molinero LM, Banares R, Albillos A. Meta-analysis: combination endoscopic and drug therapy to prevent variceal rebleeding in cirrhosis. Ann Intern Med. 2008;149(2):109–22.

    Article  PubMed  Google Scholar 

  31. Albillos A, Zamora J, Martinez J, Arroyo D, Ahmad I, De-la-Peña J, et al. Stratifying risk in the prevention of recurrent variceal hemorrhage: results of an individual patient meta-analysis. Hepatology. 2017;66(4):1219–31. https://doi.org/10.1002/hep.29267.

    Article  CAS  PubMed  Google Scholar 

  32. Garcia-Pagan JC, Caca K, Bureau C, Laleman W, Appenrodt B, Luca A, et al. Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med. 2010;362(25):2379–9. https://doi.org/10.1056/NEJMoa0910102.

  33. Zipprich A, Garcia-Tsao G, Rogowsky S, Fleig WE, Seufferlein T, Dollinger MM. Prognostic indicators of survival in patients with compensated and decompensated cirrhosis. Liv Int. 2012;32(9):1407–14. https://doi.org/10.1111/j.1478-3231.2012.02830.x.

    Article  CAS  Google Scholar 

  34. Planas R, Montoliu S, Ballesté B, Rivera M, Mireia M, Masnou H, et al. Natural history of patients hospitalized for management of cirrhotic ascites. Clin Gastro Hepatol. 2006;4(11):1385–94. https://doi.org/10.1016/j.cgh.2006.08.007.

    Article  Google Scholar 

  35. •• Bernardi M, Moreau R, Angeli P, Schnabl B, Arroyo V. Mechanisms of decompensation and organ failure in cirrhosis: from peripheral arterial vasodilatation to systemic inflammation hypothesis. J Hepatol. 2015;63(5):1272–84. https://doi.org/10.1016/j.jhep.2015.07.004 This article provides a clear explanation of drawback of the peripheral arterial vasodilatory hypothesis and potential strengths of the bacterial translocation/ inflammation hypothesis in determining decompensation in liver cirrhosis.

    Article  CAS  PubMed  Google Scholar 

  36. Salerno F, Cammà C, Enea M, Rossle M, Wong F. Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data. Gastroenterology. 2007;133(3):825–34. https://doi.org/10.1053/j.gastro.2007.06.020.

    Article  CAS  PubMed  Google Scholar 

  37. Bureau C, Thabut D, Oberti F, Dharancy S, Carbonell N, Bouvier A, et al. Transjugular intrahepatic portosystemic shunts with covered stents increase transplant-free survival of patients with cirrhosis and recurrent ascites. Gastroenterology. 2017;152(1):157–63. https://doi.org/10.1053/j.gastro.2016.09.016.

    Article  PubMed  Google Scholar 

  38. Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD, et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology. 2014;60(2):715–35. https://doi.org/10.1002/hep.27210.

    Article  PubMed  Google Scholar 

  39. Thomsen KL, Macnaughtan J, Tritto G, Mookerjee RP, Jalan R. Clinical and pathophysiological characteristics of cirrhotic patients with grade 1 and minimal hepatic encephalopathy. PLoS One. 2016;11:e0146076. https://doi.org/10.1371/journal.pone.0146076 eCollection 2016.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Bajaj JS, Cordoba J, Mullen KD, Amodio P, Shawcross DL, Butterworth RF, et al. Review article: the design of clinical trials in hepatic encephalopathy--an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement. Aliment Pharmacol Ther. 2011;33(7):739–47. https://doi.org/10.1111/j.1365-2036.2011.04590.x.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Patidar KR, Thacker LR, Wade JB, Sterling RK, Sanyal AJ, Siddiqu MS, et al. Covert hepatic encephalopathy is independently associated with poor survival and increased risk of hospitalization. Am J Gastroenterol. 2014;109(11):1757–63. https://doi.org/10.1038/ajg.2014.264.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Piano S, Rosi S, Maresio G, Fasolato S, Cavallin M, Romano A, et al. Evaluation of the acute kidney injury network criteria in hospitalized patients with cirrhosis and ascites. J Hepatol. 2013;59(3):482–9. https://doi.org/10.1016/j.jhep.2013.03.039.

    Article  PubMed  Google Scholar 

  43. Fagundes C, Barreto R, Guevara M, Garcia E, Solà E, Rodríguez E, et al. A modified acute kidney injury classification for diagnosis and risk stratification of impairment of kidney function in cirrhosis. J Hepatol. 2013;59(3):474–81. https://doi.org/10.1016/j.jhep.2013.04.036.

    Article  PubMed  Google Scholar 

  44. Angeli P, Ginès P, Wong F, Bernardi M, Boyer TD, Gerbes A, et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. J Hepatol. 2015;62(4):968–74. https://doi.org/10.1016/j.jhep.2014.12.029.

    Article  PubMed  Google Scholar 

  45. Tsien CD, Rabie R, Wong F. Acute kidney injury in decompensated cirrhosis. Gut. 2013;62(1):131–7. https://doi.org/10.1136/gutjnl-2011-301255.

    Article  PubMed  Google Scholar 

  46. Fede G, D’Amico G, Arvaniti V, Tsochatzis E, Germani G, Georgiadis D, et al. Renal failure and cirrhosis: a systematic review of mortality and prognosis. J Hepatol. 2012;56(4):810–8. https://doi.org/10.1016/j.jhep.2011.10.016.

    Article  PubMed  Google Scholar 

  47. Salerno F, Cazzaniga M, Merli M, Spinzi G, Saibeni S, Salmi S, et al. Diagnosis, treatment and survival of patients with hepatorenal syndrome: a survey on daily medical practice. J Hepatol. 2011;55(6):1241–8. https://doi.org/10.1016/j.jhep.2011.03.012.

    Article  CAS  PubMed  Google Scholar 

  48. Wiest R, Lawson M, Geuking M. Pathological bacterial translocation in liver cirrhosis. J Hepatol. 2014;60(1):197–209. https://doi.org/10.1016/j.jhep.2013.07.044.

    Article  PubMed  Google Scholar 

  49. Dionigi E, Garcovich M, Borzio M, Leandro G, Majumdar A, Tsami A, et al. Bacterial infections change natural history of cirrhosis irrespective of liver disease severity. Am J Gatroenterol. 2017;112(4):588–96. https://doi.org/10.1038/ajg.2017.19.

    Article  Google Scholar 

  50. Bajaj JS, O’Leary JG, Wong F, Reddy KR, Kamath PS. Bacterial infections in end-stage liver disease: current challenges and future directions. Gut. 2012;61(8):1219–25. https://doi.org/10.1136/gutjnl-2012-302339.

    Article  CAS  PubMed  Google Scholar 

  51. Fernandez J, Navasa M, Gomez J, Colmenero J, Vila J, Arroyo V, et al. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology. 2002;35(1):140–8. https://doi.org/10.1053/jhep.2002.30082.

    Article  PubMed  Google Scholar 

  52. Piano S, Morando F, Carretta G, Tonon N, Vettore E, Rosi S, et al. Predictors of early readmission in patients with cirrhosis after the resolution of bacterial infections. Am J Gastroenterol. 2017;112(10):1575–83. https://doi.org/10.1038/ajg.2017.253.

    Article  PubMed  Google Scholar 

  53. Arvaniti V, D’Amico G, Fede G, Manosou P, Tsochatzis E, Pleguezuelo M, et al. Infections in patients with cirrhosis increases mortality four-fold and should be used in determining prognosis. Gastroenterology. 2010;139(4):1246–56. https://doi.org/10.1053/j.gastro.2010.06.019.

    Article  PubMed  Google Scholar 

  54. Zhao C, Nguyen MH. Hepatocellular carcinoma screening and surveillance: practice guidelines and real-life practice. J Clin Gastroenterol. 2016;50(2):120–33. https://doi.org/10.1097/MCG.0000000000000446.

    Article  CAS  PubMed  Google Scholar 

  55. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004;127(5 Suppl 1):S35–50.

    Article  PubMed  Google Scholar 

  56. Ioannou GN, Splan MF, Weiss NS, McDonald GB, Beretta L, Lee SP. Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol. 2007;5(8):938–45. https://doi.org/10.1016/j.cgh.2007.02.039.

    Article  PubMed  Google Scholar 

  57. Giannini EG, Farinati F, Ciccarese F, Pecorelli A, Rapaccini GL, Di Marco M, et al. Prognosis of untreated hepatocellular carcinoma. Hepatology. 2015;61(1):184–90. https://doi.org/10.1002/hep.27443.

    Article  PubMed  Google Scholar 

  58. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19(3):329–38. https://doi.org/10.1055/s-2007-1007122.

    Article  CAS  PubMed  Google Scholar 

  59. Moreau R, Jalan R, Gines P, Pavesi M, Angeli P, Cordoba J, et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology. 2013;144(7):1426–37. https://doi.org/10.1053/j.gastro.2013.02.042.

    Article  PubMed  Google Scholar 

  60. Arroyo V, Jalan R. Acute-on-chronic liver failure: definition, diagnosis and clinical characteristics. Semin Liver Dis. 2016;36(2):109–16. https://doi.org/10.1055/s-0036-1583202.

    Article  PubMed  Google Scholar 

  61. Hernaez R, Solà E, Moreau R, Ginès P. Acute-on-chronic liver failure: an update. Gut. 2017;66(3):541–53. https://doi.org/10.1136/gutjnl-2016-312670.

    Article  CAS  PubMed  Google Scholar 

  62. •• Clària J, Stauber ER, Coenraad MJ, Moreau R, Jalan R, Pavesi M, et al. Systemic inflammation in decompensated cirrhosis: characterization and role in acute-on-chronic liver failure. Hepatology. 2016;64(4):1249–64. https://doi.org/10.1002/hep.28740 Provides evidence for the inflammatory hypothesis for decompensation of cirrhosis.

    Article  CAS  PubMed  Google Scholar 

  63. Solé C, Solà E, Morales-Ruiz M, Fernandez G, Huelin P, Graupera I, et al. Characterization of inflammatory response in acute-on-chronic liver failure and relationship with prognosis. Sci Rep. 2016;6:32341. https://doi.org/10.1038/srep32341.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Moreau R. The pathogenesis of ACLF: the inflammatory response and immune function. Semin Liver Dis. 2016;36(2):133–40. https://doi.org/10.1055/s-0036-1583199.

    Article  CAS  PubMed  Google Scholar 

  65. Clària J, Arroyo V, Moreau R. The acute-on-chronic liver failure syndrome, or when the innate immune system goes astray. J Immunol. 2016;197(10):3755–61. https://doi.org/10.4049/jimmunol.1600818.

    Article  CAS  PubMed  Google Scholar 

  66. • Piano S, Tonon M, Vettore E, Stanco M, Pilutti C, Romano A, et al. Incidence, predictors and outcome of acute-on-chronic liver failure in outpatients with cirrhosis. J Hepatol. 2017;67(6):1177–84. https://doi.org/10.1016/j.jhep.2017.07.008 First study addressing the incidence rate of acute on chronic liver failure in compensated cirrhosis.

    Article  PubMed  Google Scholar 

  67. Al Mamari S, Djordjevic J, Halliday JS, Chapman RW. Improvement of serum alkaline phosphatase to <1.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitis. J Hepatol. 2013;58(2):329–34. https://doi.org/10.1016/j.jhep.2012.10.013.

    Article  CAS  PubMed  Google Scholar 

  68. Ampuero J, Montoliú C, Simón-Talero M, Aguilera V, Millán R, Márquez C, et al. Minimal hepatic encephalopathy identifies patients at risk of faster cirrhosis progression. J Gastroenterol Hepatol. 2018;33(3):718–25. https://doi.org/10.1111/jgh.13917.

    Article  PubMed  Google Scholar 

  69. Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149(2):389–97.e10. https://doi.org/10.1053/j.gastro.2015.04.043.

    Article  PubMed  Google Scholar 

  70. Bang UC, Benfield T, Bendtsen F. Reduced risk of decompensation and death associated with use of statins in patients with alcoholic cirrhosis. A nationwide case-cohort study. Aliment Pharmacol Ther. 2017;46(7):673–80. https://doi.org/10.1111/apt.14243.

    Article  CAS  PubMed  Google Scholar 

  71. Benvegnù L, Gios M, Boccato S, Alberti A. Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut. 2004;53(5):744–9.

    Article  PubMed  PubMed Central  Google Scholar 

  72. Berzigotti A, Garcia-Tsao G, Bosch J, Grace ND, Burroughs AK, Morillas R, et al. Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis. Hepatology. 2011;54(2):555–61. https://doi.org/10.1002/hep.24418.

    Article  PubMed  Google Scholar 

  73. Berzigotti A, Rossi V, Tiani C, Pierpaoli L, Zappoli P, Riili A, et al. Prognostic value of a single HVPG measurement and Doppler-ultrasound evaluation in patients with cirrhosis and portal hypertension. J Gastroenterol. 2011;46(5):687–95. https://doi.org/10.1007/s00535-010-0360-z.

    Article  PubMed  Google Scholar 

  74. Berzigotti A, Zappoli P, Magalotti D, Tiani C, Rossi V, Zoli M. Spleen enlargement on follow-up evaluation: a noninvasive predictor of complications of portal hypertension in cirrhosis. Clin Gastroenterol Hepatol. 2008;6(10):1129–34. https://doi.org/10.1016/j.cgh.2008.05.004.

    Article  PubMed  Google Scholar 

  75. Braks RE, Ganne-Carrie N, Fontaine H, Paries J, Grando-Lemaire V, Beaugrand M, et al. Effect of sustained virological response on long-term clinical outcome in 113 patients with compensated hepatitis C-related cirrhosis treated by interferon alpha and ribavirin. World J Gastroenterol. 2007;13(42):5648–53.

    Article  PubMed  PubMed Central  Google Scholar 

  76. Brancaccio G, Fasano M, Grossi A, Santantonio TA, Gaeta GB. Clinical outcomes in patients with hepatitis D, cirrhosis and persistent hepatitis B virus replication, and receiving long-term tenofovir or entecavir. Aliment Pharmacol Ther. 2019. https://doi.org/10.1111/apt.15188.

  77. Bruno S, Zuin M, Crosignani A, Rossi S, Zadra F, Roffi L, et al. Predicting mortality risk in patients with compensated HCV-induced cirrhosis: a long-term prospective study. Am J Gastroenterol. 2009;104(5):1147–58. https://doi.org/10.1038/ajg.2009.31.

    Article  PubMed  Google Scholar 

  78. Cacciola I, Filomia R, Alibrandi A, Franzè MS, Caccamo G, Maimone S, et al. Hypergammaglobulinemia is a strong predictor of disease progression, hepatocellular carcinoma, and death in patients with compensated cirrhosis. Liver Int. 2018;38(7):1220–9. https://doi.org/10.1111/liv.13649.

    Article  CAS  PubMed  Google Scholar 

  79. Calvaruso V, Di Marco V, Bavetta MG, Cabibi D, Conte E, Bronte F, et al. Quantification of fibrosis by collagen proportionate area predicts hepatic decompensation in hepatitis C cirrhosis. Aliment Pharmacol Ther. 2015;41(5):477–86. https://doi.org/10.1111/apt.13051.

    Article  CAS  PubMed  Google Scholar 

  80. Calzadilla-Bertot L, Vilar-Gomez E, Torres-Gonzalez A, Socias-Lopez M, Diago M, Adams LA, et al. Impaired glucose metabolism increases risk of hepatic decompensation and death in patients with compensated hepatitis C virus-related cirrhosis. Dig Liver Dis. 2016;48(3):283–90. https://doi.org/10.1016/j.dld.2015.12.002.

    Article  CAS  PubMed  Google Scholar 

  81. Chang FM, Wang YP, Lang HC, Tsai CF, Hou MC, Lee FY, et al. Statins decrease the risk of decompensation in hepatitis B virus- and hepatitis C virus-related cirrhosis: a population-based study. Hepatology. 2017;66(3):896–907. https://doi.org/10.1002/hep.29172.

    Article  CAS  PubMed  Google Scholar 

  82. Chang PE, Wong GW, Li JW, Lui HF, Chow WC, Tan CK. Epidemiology and clinical evolution of liver cirrhosis in Singapore. Ann Acad Med Singap. 2015;44(6):218–25.

    PubMed  Google Scholar 

  83. Chen YC, Chu CM, Yeh CT, Liaw YF. Natural course following the onset of cirrhosis in patients with chronic hepatitis B: a long-term follow-up study. Hepatol Int. 2007;1(1):267–73. https://doi.org/10.1007/s12072-007-5001-0.

    Article  PubMed  PubMed Central  Google Scholar 

  84. Cheung AC, Lapointe-Shaw L, Kowgier M, Meza-Cardona J, Hirschfield GM, Janssen HL, et al. Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes. Aliment Pharmacol Ther. 2016;43(2):283–93. https://doi.org/10.1111/apt.13465.

    Article  CAS  PubMed  Google Scholar 

  85. Colecchia A, Colli A, Casazza G, Mandolesi D, Schiumerini R, Reggiani LB, et al. Spleen stiffness measurement can predict clinical complications in compensated HCV-related cirrhosis: a prospective study. J Hepatol. 2014;60(6):1158–64. https://doi.org/10.1016/j.jhep.2014.02.024.

    Article  PubMed  Google Scholar 

  86. D'Amico G, Morabito A, Pagliaro L, Marubini E. Survival and prognostic indicators in compensated and decompensated cirrhosis. Dig Dis Sci. 1986;31(5):468–75.

    Article  CAS  PubMed  Google Scholar 

  87. D'Amico G, Pasta L, Morabito A, D'Amico M, Caltagirone M, Malizia G, et al. Competing risks and prognostic stages of cirrhosis: a 25-year inception cohort study of 494 patients. Aliment Pharmacol Ther. 2014;39(10):1180–93. https://doi.org/10.1111/apt.12721.

    Article  CAS  PubMed  Google Scholar 

  88. Di Marco V, Calvaruso V, Ferraro D, Bavetta MG, Cabibbo G, Conte E, et al. Effects of eradicating hepatitis C virus infection in patients with cirrhosis differ with stage of portal hypertension. Gastroenterology. 2016;151(1):130–139.e2. https://doi.org/10.1053/j.gastro.2016.03.036.

    Article  PubMed  Google Scholar 

  89. Di Marco V, Marzano A, Lampertico P, Andreone P, Santantonio T, Almasio PL, et al. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology. 2004;40(4):883–91. https://doi.org/10.1002/hep.20381.

    Article  CAS  PubMed  Google Scholar 

  90. Eaton JE, McCauley BM, Atkinson EJ, Juran BD, Schlicht EM, de Andrade M, et al. Variations in primary sclerosing cholangitis across the age spectrum. J Gastroenterol Hepatol. 2017;32(10):1763–8. https://doi.org/10.1111/jgh.13774.

    Article  PubMed  PubMed Central  Google Scholar 

  91. Fartoux L, Degos F, Trépo C, Goria O, Calès P, Tran A, et al. Effect of prolonged interferon therapy on the outcome of hepatitis C virus-related cirrhosis: a randomized trial. Clin Gastroenterol Hepatol. 2007;5(4):502–7. https://doi.org/10.1016/j.cgh.2006.10.016.

    Article  CAS  PubMed  Google Scholar 

  92. Fattovich G, Giustina G, Christensen E, Pantalena M, Zagni I, Realdi G, et al. Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis (Eurohep). Gut. 2000;46(3):420–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  93. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology. 1997;112(2):463–72.

    Article  CAS  PubMed  Google Scholar 

  94. Fattovich G, Giustina G, Schalm SW, Hadziyannis S, Sanchez-Tapias J, Almasio P, et al. Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP Study Group on Hepatitis B Virus and Cirrhosis. Hepatology. 1995;21(1):77–82.

    CAS  PubMed  Google Scholar 

  95. Fattovich G, Pantalena M, Zagni I, Realdi G, Schalm SW, Christensen E, et al. Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. Am J Gastroenterol. 2002;97(11):2886–95. https://doi.org/10.1111/j.1572-0241.2002.07057.x.

    Article  PubMed  Google Scholar 

  96. Ferlitsch M, Reiberger T, Hoke M, Salzl P, Schwengerer B, Ulbrich G, et al. von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis. Hepatology. 2012;56(4):1439–47. https://doi.org/10.1002/hep.25806.

    Article  CAS  PubMed  Google Scholar 

  97. Fernández-Rodríguez CM, Alonso S, Martinez SM, Forns X, Sanchez-Tapias JM, Rincón D, et al. Peginterferon plus ribavirin and sustained virological response in HCV-related cirrhosis: outcomes and factors predicting response. Am J Gastroenterol. 2010;105(10):2164–72; quiz 2173. https://doi.org/10.1038/ajg.2010.294.

    Article  CAS  PubMed  Google Scholar 

  98. Fleming KM, Aithal GP, Card TR, West J. The rate of decompensation and clinical progression of disease in people with cirrhosis: a cohort study. Aliment Pharmacol Ther. 2010;32(11–12):1343–50. https://doi.org/10.1111/j.1365-2036.2010.04473.x.

    Article  CAS  PubMed  Google Scholar 

  99. Ghany MG, Kim HY, Stoddard A, Wright EC, Seeff LB, Lok AS, et al. Predicting clinical outcomes using baseline and follow-up laboratory data from the hepatitis C long-term treatment against cirrhosis trial. Hepatology. 2011;54(5):1527–37. https://doi.org/10.1002/hep.24550.

    Article  PubMed  Google Scholar 

  100. Gheorghe L, Iacob S, Simionov I, Vadan R, Gheorghe C, Iacob R, et al. Natural history of compensated viral B and D cirrhosis. Rom J Gastroenterol. 2005;14(4):329–35.

    PubMed  Google Scholar 

  101. Ginés P, Quintero E, Arroyo V, Terés J, Bruguera M, Rimola A, et al. Compensated cirrhosis: natural history and prognostic factors. Hepatology. 1987;7(1):122–8.

    Article  PubMed  Google Scholar 

  102. Guha IN, Harris R, Berhane S, Dillon A, Coffey L, James MW, et al. Validation of a model for identification of patients with compensated cirrhosis at high risk of decompensation. Clin Gastroenterol Hepatol. 2019. https://doi.org/10.1016/j.cgh.2019.01.042.

  103. Hagström H, Nasr P, Ekstedt M, Hammar U, Stål P, Hultcrantz R, et al. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J Hepatol. 2017;67(6):1265–73. https://doi.org/10.1016/j.jhep.2017.07.027.

    Article  PubMed  Google Scholar 

  104. Hallager S, Ladelund S, Christensen PB, Kjær M, Thorup Roege B, Grønbæk KE, et al. Liver-related morbidity and mortality in patients with chronic hepatitis C and cirrhosis with and without sustained virologic response. Clin Epidemiol. 2017;9:501–16. https://doi.org/10.2147/CLEP.S132072 eCollection 2017.

    Article  PubMed  PubMed Central  Google Scholar 

  105. Harms MH, Lammers WJ, Thorburn D, Corpechot C, Invernizzi P, Janssen HLA, et al. Major hepatic complications in ursodeoxycholic acid-treated patients with primary biliary cholangitis: risk factors and time trends in incidence and outcome. Am J Gastroenterol. 2018;113(2):254–64. https://doi.org/10.1038/ajg.2017.440.

    Article  PubMed  Google Scholar 

  106. Hernández-Gea V, Aracil C, Colomo A, Garupera I, Poca M, Torras X, et al. Development of ascites in compensated cirrhosis with severe portal hypertension treated with β-blockers. Am J Gastroenterol. 2012;107(3):418–27. https://doi.org/10.1038/ajg.2011.456.

    Article  CAS  PubMed  Google Scholar 

  107. Hu KQ, Tong MJ. The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States. Hepatology. 1999;29(4):1311–6.

    Article  CAS  PubMed  Google Scholar 

  108. Kaplan DE, Serper M, Mehta R, Fox R, John B, Aytaman A, et al. Effects of hypercholesterolemia and statin exposure on survival in a large national cohort of patients with cirrhosis. Gastroenterology. 2019. https://doi.org/10.1053/j.gastro.2019.01.026.

  109. Kim BK, Park YN, Kim DY, Park JY, Chon CY, Han KH, et al. Risk assessment of development of hepatic decompensation in histologically proven hepatitis B viral cirrhosis using liver stiffness measurement. Digestion. 2012;85(3):219–27. https://doi.org/10.1159/000335430.

    Article  PubMed  Google Scholar 

  110. Kim YS, Um SH, Ryu HS, Lee JB, Lee JW, Park DK, et al. The prognosis of liver cirrhosis in recent years in Korea. J Korean Med Sci. 2003;18(6):833–41. https://doi.org/10.3346/jkms.2003.18.6.833.

    Article  PubMed  PubMed Central  Google Scholar 

  111. King LY, Canasto-Chibuque C, Johnson KB, Yip S, Chen X, Kojima K, et al. A genomic and clinical prognostic index for hepatitis C-related early-stage cirrhosis that predicts clinical deterioration. Gut. 2015;64(8):1296–302. https://doi.org/10.1136/gutjnl-2014-307862.

    Article  CAS  PubMed  Google Scholar 

  112. Kondo T, Maruyama H, Sekimoto T, Shimada T, Takahashi M, Okugawa H, et al. Impact of portal hemodynamics on Doppler ultrasonography for predicting decompensation and long-term outcomes in patients with cirrhosis. Scand J Gastroenterol. 2016;51(2):236–44. https://doi.org/10.3109/00365521.2015.1081275.

    Article  PubMed  Google Scholar 

  113. Lee MH, Tae HJ, Jun DW, Ryu SE, Choi YY, Kwak MJ, et al. 201Tl heart-liver radioactivity uptake ratio and prediction of decompensation in patients with cirrhosis. Clin Nucl Med. 2013;38(3):169–74. https://doi.org/10.1097/RLU.0b013e31827087e3.

    Article  PubMed  Google Scholar 

  114. Lens S, Rincón D, García-Retortillo M, Albillos A, Calleja JL, Bañares R, et al. Association between severe portal hypertension and risk of liver decompensation in patients with hepatitis C, regardless of response to antiviral therapy. Clin Gastroenterol Hepatol. 2015;13(10):1846–1853.e1. https://doi.org/10.1016/j.cgh.2015.04.013.

    Article  PubMed  Google Scholar 

  115. Liaw YF, Lin DY, Chen TJ, Chu CM. Natural course after the development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Liver. 1989;9(4):235–41.

    Article  CAS  PubMed  Google Scholar 

  116. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351(15):1521–31. https://doi.org/10.1056/NEJMoa033364.

    Article  CAS  PubMed  Google Scholar 

  117. Lisotti A, Azzaroli F, Cucchetti A, Buonfiglioli F, Cecinato P, Calvanese C, et al. Relationship between indocyanine green retention test, decompensation and survival in patients with Child-Pugh A cirrhosis and portal hypertension. Liver Int. 2016;36(9):1313–21. https://doi.org/10.1111/liv.13070.

    Article  CAS  PubMed  Google Scholar 

  118. Liu TL, Trogdon J, Weinberger M, Fried B, Barritt AS 4th. Diabetes is associated with clinical decompensation events in patients with cirrhosis. Dig Dis Sci. 2016;61(11):3335–45. https://doi.org/10.1007/s10620-016-4261-8.

    Article  PubMed  Google Scholar 

  119. López-Diéguez M, Montes ML, Pascual-Pareja JF, Quereda C, Von Wichmann MA, Berenguer J, et al. The natural history of liver cirrhosis in HIV-hepatitis C virus-coinfected patients. AIDS. 2011;25(7):899–904. https://doi.org/10.1097/QAD.0b013e3283454174.

    Article  PubMed  Google Scholar 

  120. Macías J, Camacho A, Von Wichmann MA, López-Cortés LF, Ortega E, Tural C, et al. Liver stiffness measurement versus liver biopsy to predict survival and decompensations of cirrhosis among HIV/hepatitis C virus-coinfected patients. AIDS. 2013;27(16):2541–9. https://doi.org/10.1097/QAD.0b013e32836381f3.

    Article  PubMed  Google Scholar 

  121. Merchante N, Aldámiz-Echevarría T, García-Álvarez M, Rivero-Juárez A, Macías J, Miralles P, et al. Bacterial translocation and clinical progression of HCV-related cirrhosis in HIV-infected patients. J Viral Hepat. 2018;25(2):180–6. https://doi.org/10.1111/jvh.12769.

    Article  CAS  PubMed  Google Scholar 

  122. Merchante N, Rivero-Juárez A, Téllez F, Merino D, José Ríos-Villegas M, Márquez-Solero M, et al. Liver stiffness predicts clinical outcome in human immunodeficiency virus/hepatitis C virus-coinfected patients with compensated liver cirrhosis. Hepatology. 2012;56(1):228–38. https://doi.org/10.1002/hep.25616.

    Article  PubMed  Google Scholar 

  123. Merchante N, Téllez F, Rivero-Juárez A, Ríos-Villegas MJ, Merino D, Márquez-Solero M, et al. Progression of liver stiffness predicts clinical events in HIV/HCV-coinfected patients with compensated cirrhosis. BMC Infect Dis. 2015;15:557. https://doi.org/10.1186/s12879-015-1291-3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  124. Mira JA, Rivero-Juárez A, López-Cortés LF, Girón-González JA, Téllez F, de los Santos-Gil I, et al. Benefits from sustained virologic response to pegylated interferon plus ribavirin in HIV/hepatitis C virus-coinfected patients with compensated cirrhosis. Clin Infect Dis. 2013;56(11):1646–53. https://doi.org/10.1093/cid/cit103.

    Article  CAS  PubMed  Google Scholar 

  125. Mohanty A, Tate JP, Garcia-Tsao G. Statins are associated with a decreased risk of decompensation and death in veterans with hepatitis C-related compensated cirrhosis. Gastroenterology. 2016;150(2):430–40.e1. https://doi.org/10.1053/j.gastro.2015.10.007.

    Article  CAS  PubMed  Google Scholar 

  126. Murillo Perez CF, Goet JC, Lammers WJ, Gulamhusein A, van Buuren HR, Ponsioen CY, et al. Milder disease stage in patients with primary biliary cholangitis over a 44-year period: a changing natural history. Hepatology. 2018;67(5):1920–30. https://doi.org/10.1002/hep.29717.

    Article  CAS  PubMed  Google Scholar 

  127. Nahon P, Bourcier V, Layese R, Audureau E, Cagnot C, Marcellin P, et al. Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications. Gastroenterology. 2017;152(1):142–156.e2. https://doi.org/10.1053/j.gastro.2016.09.009.

    Article  PubMed  Google Scholar 

  128. Nahon P, Lescat M, Layese R, Bourcier V, Talmat N, Allam S, et al. Bacterial infection in compensated viral cirrhosis impairs 5-year survival (ANRS CO12 CirVir prospective cohort). Gut. 2017;66(2):330–41. https://doi.org/10.1136/gutjnl-2015-310275.

    Article  PubMed  Google Scholar 

  129. Nilsson E, Anderson H, Sargenti K, Lindgren S, Prytz H. Patients with liver cirrhosis show worse survival if decompensation occurs later during course of disease than at diagnosis. Scand J Gastroenterol. 2018;53(4):475–81. https://doi.org/10.1080/00365521.2018.1447599.

    Article  PubMed  Google Scholar 

  130. Niro GA, Smedile A, Ippolito AM, Ciancio A, Fontana R, Olivero A, et al. Outcome of chronic delta hepatitis in Italy: a long-term cohort study. J Hepatol. 2010;53(5):834–40. https://doi.org/10.1016/j.jhep.2010.06.008.

    Article  PubMed  Google Scholar 

  131. Papatheodoridis GV, Hadziyannis ES, Deutsch M, Hadziyannis SJ. Ursodeoxycholic acid for primary biliary cirrhosis: final results of a 12-year, prospective, randomized, controlled trial. Am J Gastroenterol. 2002;97(8):2063–70. https://doi.org/10.1111/j.1572-0241.2002.05923.x.

    Article  CAS  PubMed  Google Scholar 

  132. Pérez-Latorre L, Sánchez-Conde M, Rincón D, Miralles P, Aldámiz-Echevarría T, Carrero A, et al. Prediction of liver complications in patients with hepatitis C virus-related cirrhosis with and without HIV coinfection: comparison of hepatic venous pressure gradient and transient elastography. Clin Infect Dis. 2014;58(5):713–8. https://doi.org/10.1093/cid/cit768.

    Article  PubMed  Google Scholar 

  133. Petta S, Di Marco V, Bruno S, Enea M, Calvaruso V, Boccaccio V, et al. Impact of virus eradication in patients with compensated hepatitis C virus-related cirrhosis: competing risks and multistate model. Liver Int. 2016;36(12):1765–73. https://doi.org/10.1111/liv.13156.

    Article  PubMed  Google Scholar 

  134. Pineda JA, Aguilar-Guisado M, Rivero A, Girón-González JA, Ruiz-Morales J, Merino D, et al. Natural history of compensated hepatitis C virus-related cirrhosis in HIV-infected patients. Clin Infect Dis. 2009;49(8):1274–82. https://doi.org/10.1086/605676.

    Article  PubMed  Google Scholar 

  135. Rincón D, Lo Iacono O, Tejedor M, Hernando A, Ripoll C, Catalina MV, et al. Prognostic value of hepatic venous pressure gradient in patients with compensated chronic hepatitis C-related cirrhosis. Scand J Gastroenterol. 2013;48(4):487–95. https://doi.org/10.3109/00365521.2012.711848.

    Article  CAS  PubMed  Google Scholar 

  136. Ripoll C, Groszmann R, Garcia-Tsao G, Grace N, Burroughs A, Planas R, et al. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology. 2007;133(2):481–8. https://doi.org/10.1053/j.gastro.2007.05.024.

    Article  CAS  PubMed  Google Scholar 

  137. Romeo R, Del Ninno E, Rumi M, Russo A, Sangiovanni A, de Franchis R, et al. A 28-year study of the course of hepatitis delta infection: a risk factor for cirrhosis and hepatocellular carcinoma. Gastroenterology. 2009;136(5):1629–38. https://doi.org/10.1053/j.gastro.2009.01.052.

    Article  PubMed  Google Scholar 

  138. Samonakis DN, Koulentaki M, Coucoutsi C, Augoustaki A, Baritaki C, Digenakis E, et al. Clinical outcomes of compensated and decompensated cirrhosis: a long term study. World J Hepatol. 2014;6(7):504–12. https://doi.org/10.4254/wjh.v6.i7.504.

    Article  PubMed  PubMed Central  Google Scholar 

  139. Sanyal AJ, Banas C, Sargeant C, Luketic VA, Sterling RK, Stravitz RT, et al. Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology. 2006;43(4):682–9. https://doi.org/10.1002/hep.21103.

    Article  PubMed  Google Scholar 

  140. Sebastiani G, Alshaalan R, Wong P, Rubino M, Salman A, Metrakos P, et al. Prognostic value of non-invasive fibrosis and steatosis tools, hepatic venous pressure gradient (HVPG) and histology in nonalcoholic steatohepatitis. PLoS One. 2015;10(6):e0128774. https://doi.org/10.1371/journal.pone.0128774 eCollection 2015.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  141. Serfaty L, Aumaître H, Chazouillères O, Bonnand AM, Rosmorduc O, et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology. 1998;27(5):1435–40. https://doi.org/10.1002/hep.510270535.

    Article  CAS  PubMed  Google Scholar 

  142. Shi TY, Zhang LN, Chen H, Wang L, Shen M, Zhang X, et al. Risk factors for hepatic decompensation in patients with primary biliary cirrhosis. World J Gastroenterol. 2013;19(7):1111–8. https://doi.org/10.3748/wjg.v19.i7.1111.

    Article  PubMed  PubMed Central  Google Scholar 

  143. Smith AD, Zand KA, Florez E, Sirous R, Shlapak D, Souza F, et al. Liver surface nodularity score allows prediction of cirrhosis decompensation and death. Radiology. 2017;283(3):711–22. https://doi.org/10.1148/radiol.2016160799.

    Article  PubMed  Google Scholar 

  144. Takuma Y, Morimoto Y, Takabatake H, Toshikuni N, Tomokuni J, Sahara A, et al. Measurement of spleen stiffness with acoustic radiation force impulse imaging predicts mortality and hepatic decompensation in patients with liver cirrhosis. Clin Gastroenterol Hepatol. 2017;15(11):1782–1790.e4. https://doi.org/10.1016/j.cgh.2016.10.041.

    Article  PubMed  Google Scholar 

  145. Toshikuni N, Izumi A, Nishino K, Inada N, Sakanoue R, Yamato R, et al. Comparison of outcomes between patients with alcoholic cirrhosis and those with hepatitis C virus-related cirrhosis. J Gastroenterol Hepatol. 2009;24(7):1276–83. https://doi.org/10.1111/j.1440-1746.2009.05851.x.

    Article  PubMed  Google Scholar 

  146. Tsochatzis E, Bruno S, Isgro G, Hall A, Theocharidou E, Manousou P, et al. Collagen proportionate area is superior to other histological methods for sub-classifying cirrhosis and determining prognosis. J Hepatol. 2014;60(5):948–54. https://doi.org/10.1016/j.jhep.2013.12.023.

    Article  CAS  PubMed  Google Scholar 

  147. Turco L, Garcia-Tsao G, Magnani I, Bianchini M, Costetti M, Caporali C, et al. Cardiopulmonary hemodynamics and C-reactive protein as prognostic indicators in compensated and decompensated cirrhosis. J Hepatol. 2018;68(5):949–58. https://doi.org/10.1016/j.jhep.2017.12.027.

    Article  CAS  PubMed  Google Scholar 

  148. Umemura T, Sekiguchi T, Joshita S, Yamazaki T, Fujimori N, Shibata S, et al. Association between serum soluble CD14 and IL- levels and clinical outcome in primary biliarycholangitis. Liver Int. 2017;37(6):897–905. https://doi.org/10.1111/liv.13316.

    Article  CAS  PubMed  Google Scholar 

  149. Vilar-Gomez E, Calzadilla-Bertot L, Wai-Sun Wong V, Castellanos M, Aller-de la Fuente R, Metwally M, et al. Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease: a multi-national cohort study. Gastroenterology. 2018;155(2):443–457.e17. https://doi.org/10.1053/j.gastro.2018.04.034.

    Article  PubMed  Google Scholar 

  150. Vilar-Gomez E, Vuppalanchi R, Gawrieh S, Ghabril M, Saxena R, Cummings OW, et al. Vitamin E improves transplant free survival and hepatic decompensation among patients with nonalcoholic steatohepatitis and advanced fibrosis. Hepatology. 2018. https://doi.org/10.1002/hep.30368.

  151. Wang JH, Chuah SK, Lu SN, Hung CH, Kuo CM, Tai WC, et al. Baseline and serial liver stiffness measurement in prediction of portal hypertension progression for patients with compensated cirrhosis. Liver Int. 2014;34(9):1340–8. https://doi.org/10.1111/liv.12525.

    Article  PubMed  Google Scholar 

  152. Wendum D, Layese R, Ganne-Carrié N, Bourcier V, Merabtene F, Cagnot C, et al. Influence of progenitor-derived regeneration markers on hepatitis C virus-related cirrhosis outcome (ANRS CO12 CirVir cohort). Hepatology. 2018;68(4):1534–48. https://doi.org/10.1002/hep.29927.

    Article  CAS  PubMed  Google Scholar 

  153. Wong A, Le A, Lee MH, Lin YJ, Nguyen P, Trinh S, et al. Higher risk of hepatocellular carcinoma in Hispanic patients with hepatitis C cirrhosis and metabolic risk factors. Sci Rep. 2018;8(1):7164. https://doi.org/10.1038/s41598-018-25533-2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  154. Younossi Z, Stepanova M, Sanyal AJ, Harrison SA, Ratziu V, Abdelmalek MF, et al. The conundrum of cryptogenic cirrhosis: adverse outcomes without treatment options. J Hepatol. 2018;69(6):1365–70. https://doi.org/10.1016/j.jhep.2018.08.013.

    Article  PubMed  Google Scholar 

  155. Anika Wranke A, Calle Serrano B, Heidrich B, Kirschner J, Bremer B, Lehmann P, et al. Antiviral treatment and liver-related complications in hepatitis delta. Hepatology. 2017;65:414–25. https://doi.org/10.1002/hep.28876.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Gastroenterology Unit, Ospedale V. Cervello, via Trabucco, 109, 90146, Palermo, Italy

    Gennaro D’Amico

  2. Hepatology and Gastroenterology Unit, Azienda Socio-Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda, Milan, Italy

    Giovanni Perricone

  3. Liver Failure Group, UCL Institute for Liver and Digestive Health, UCL Medical School, Royal Free Hospital, London, UK

    Giovanni Perricone

Authors
  1. Gennaro D’Amico
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Giovanni Perricone
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gennaro D’Amico.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Portal Hypertension

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

D’Amico, G., Perricone, G. Prediction of Decompensation in Patients with Compensated Cirrhosis: Does Etiology Matter?. Curr Hepatology Rep 18, 144–156 (2019). https://doi.org/10.1007/s11901-019-00473-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11901-019-00473-1

Keywords

Search

Navigation